



PHARMACEUTICAL 2021











PHARMACEUTICAL 2021





The relative strengths and weaknesses of Pulmatrix Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Pulmatrix Inc. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 97% points. The greatest weakness of Pulmatrix Inc. is the variable Other Net Income, reducing the Economic Capital Ratio by 135% points.

The company's Economic Capital Ratio, given in the ranking table, is -199%, being 156% points above the market average of -355%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 32,538 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 3,577 |
| Liabilities, Current | 8,254 |
| Liabilities, Non-Current | 608 |
| Other Assets | 1,693 |
| Other Compr. Net Income | 0 |
| Other Expenses | 0 |
| Other Liabilities | 6,168 |
| Other Net Income | -9,446 |
| Property and Equipment | 361 |
| Research and Development | 15,609 |
| Revenues | 12,634 |
| Selling, General and Administrative Expense | 6,887 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 38,169 |
| Liabilities | 15,030 |
| Expenses | 22,496 |
| Stockholders Equity | 23,139 |
| Net Income | -19,308 |
| Comprehensive Net Income | -19,308 |
| Economic Capital Ratio | -199% |

